{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:37:52Z","timestamp":1787726272658,"version":"build-2784847793"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>Some eyes with neovascular age-related macular degeneration (nAMD) and centre-involving diabetic macular oedema (DMO) fail to respond sufficiently or lose response over time to standard of care intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy. This paper explores clinical scenarios for switching to dual action angiopoietin-2 (Ang-2)\/VEGF-A inhibitor faricimab (Vabysmo, Roche Products Limited) in previously anti-VEGF-treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A national steering group meeting of UK retina specialists was held in London on 27 October 2023. Clinician practice and experience were reviewed together with pivotal clinical trial data and early findings from real-world settings. Roche Products Limited facilitated and funded the meeting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>While there is no standardised protocol for identifying suboptimal response, the authors review relevant clinical biomarkers of disease activity used in routine clinical practice to determine patient response and guide treatment decisions. Common reasons identified for considering a change of treatment were lack of efficacy demonstrated by suboptimal anatomic or visual improvement and insufficient durability of response. The panel outline strategies for switching to faricimab among eligible patients with a prior anti-VEGF treatment history, with initial monthly loading doses or maintaining the previous treatment interval before attempting to extend, that may be integrated into current treat-and-extend (T&amp;E) clinical pathways for treating patients with nAMD and DMO. General considerations for switching between treatments are also reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinicians may consider a treatment switch to faricimab in nAMD and DMO patients who have suboptimal disease control or insufficient durability of response on initial anti-VEGF therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-024-03223-w","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T08:02:52Z","timestamp":1725004972000},"page":"3077-3086","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists"],"prefix":"10.1038","volume":"38","author":[{"given":"Louise","family":"Downey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-0659","authenticated-orcid":false,"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramandeep","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2141-4512","authenticated-orcid":false,"given":"Clare","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Elsherbiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jignesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5662-5374","authenticated-orcid":false,"given":"Giuliana","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Lucie","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwyn","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Khokhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5541-4305","authenticated-orcid":false,"given":"Andrew","family":"Lotery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"3223_CR1","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144\u201367.","journal-title":"Br J Ophthalmol"},{"key":"3223_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000458539","volume":"237","author":"U Schmidt-Erfurth","year":"2017","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185\u2013222.","journal-title":"Ophthalmologica"},{"key":"3223_CR3","first-page":"CD007419","volume":"2023","author":"G Virgili","year":"2023","unstructured":"Virgili G, Curran K, Lucenteforte E, Peto T, Parravano M. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2023;2023:CD007419.","journal-title":"Cochrane Database Syst Rev"},{"key":"3223_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/cells10051049","volume":"10","author":"JO Wallsh","year":"2021","unstructured":"Wallsh JO, Gallemore RP. Anti-VEGF-resistant retinal diseases: a review of the latest treatment options. Cells. 2021;10:1049.","journal-title":"Cells"},{"key":"3223_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03937-7","volume":"21","author":"LM Khachigian","year":"2023","unstructured":"Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21:133.","journal-title":"J Transl Med"},{"key":"3223_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/iovs.64.5.28","volume":"64","author":"D Sharma","year":"2023","unstructured":"Sharma D, Zachary I, Jia H. Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases. Investig Ophthalmol Vis Sci. 2023;64:28.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3223_CR7","unstructured":"Vabysmo 120 mg\/mL solution for injection [Summary of Product Characteristics]; Roche Products Limited, UK, January 2024."},{"key":"3223_CR8","unstructured":"Vabysmo 120 mg\/mL solution for injection [Summary of Product Characteristics]; Roche Registration GmbH, Germany, June 2023."},{"key":"3223_CR9","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/OPTH.S231801","volume":"15","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA, et al. Angiopoietins as potential targets in management of retinal disease. Clin Ophthalmol. 2021;15:3747\u201355.","journal-title":"Clin Ophthalmol"},{"key":"3223_CR10","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8:1265\u201388.","journal-title":"EMBO Mol Med"},{"key":"3223_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye. 2021;35:1305\u201316.","journal-title":"Eye"},{"key":"3223_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","volume":"41","author":"JS Heier","year":"2021","unstructured":"Heier JS, Singh RP, Wykoff CC, Csaky KG, Lai TYY, Loewenstein A, et al. The angiopoietin\/tie pathway in retinal vascular diseases: a review. Retina. 2021;41:1\u201319.","journal-title":"Retina"},{"key":"3223_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/bjo.2004.049940","volume":"89","author":"JI Patel","year":"2005","unstructured":"Patel JI, Hykin PG, Gregor ZJ, Boulton M, Cree IA. Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol. 2005;89:480\u20133.","journal-title":"Br J Ophthalmol"},{"key":"3223_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","volume":"16","author":"P Saharinen","year":"2017","unstructured":"Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov. 2017;16:635\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"3223_CR15","doi-asserted-by":"crossref","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"3223_CR16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al; YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741\u201355.","journal-title":"Lancet"},{"key":"3223_CR17","unstructured":"Khanani AM, Haskova Z, Kotecha A, Margaron P, Ives J, Tan Y, et al. Faricimab in nAMD and DME: latest updates. Paper presented at Angiogenesis, Exudation, and Degeneration 2023 virtual meeting; 10\u201311 February 2023."},{"key":"3223_CR18","doi-asserted-by":"crossref","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, et al. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024;131:708\u201323.","DOI":"10.1016\/j.ophtha.2023.12.026"},{"key":"3223_CR19","unstructured":"Gale R, London N, Kotecha A, Willis JR, Souverain A, Shildkrot Y, et al. Faricimab rapidly improves fluid parameters in patients with nAMD. Paper presented at 23rd European Society of Retina Specialists Congress; Amsterdam, The Netherlands: 5\u20138 October 2023."},{"key":"3223_CR20","unstructured":"Lanzetta P, Rachitskaya A, Camino A, Gibson K, Mar F, Shildkrot Y, et al. Faster time to retinal fluid control with faricimab versus aflibercept in patients with DMO in the phase 3 YOSEMITE\/RHINE Trials. Paper presented at 23rd European Society of Retina Specialists Congress; Amsterdam, The Netherlands: 5\u20138 October 2023."},{"key":"3223_CR21","unstructured":"Nudleman N, Goldberg R, Csaky K, Kolomeyer AM, Gibson K, Mar F, et al. Faricimab reduces macular leakage vs aflibercept in patients with DME. Paper presented at American Society of Retina Specialists annual meeting; Seattle, WA, USA: 28 July\u20131 August 2023."},{"key":"3223_CR22","unstructured":"Jaffe GJ, Ogura Y, De\u00e1k G, Gibson K, Schmidt-Erfurth U, Wang T, et al. Impact of faricimab vs aflibercept on epiretinal membrane formation over 2 years in eyes with DMO in the YOSEMITE\/RHINE phase 3 trials. Paper presented at American Society of Retina Specialists annual meeting; Seattle, WA, USA: 28 July\u20131 August 2023."},{"key":"3223_CR23","first-page":"PB0039","volume":"64","author":"A Maunz","year":"2023","unstructured":"Maunz A, von Schulthess E, Patel KM, Chakravarthy U, Bachmeier I, Lloyd Jones I, et al. Automated segmentation of hyperreflective foci in diabetic macular edema shows greater volume reduction by faricimab vs aflibercept in phase 3 YOSEMITE and RHINE. Investig Ophthalmol Vis Sci. 2023;64:PB0039.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3223_CR24","unstructured":"Chakravarthy U, Maunz A, von Schulthess E, Patel K, Bachmeier I, Lloyd Jones I, et al. Automated segmentation of hyperreflective foci in DME shows greater volume reduction in eyes treated with faricimab compared to aflibercept in the phase 3 YOSEMITE and RHINE clinical trials. Paper presented at 23rd European Society of Retina Specialists Congress; Amsterdam, The Netherlands: 5\u20138 October 2023."},{"key":"3223_CR25","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1007\/s12325-023-02675-y","volume":"40","author":"C Watkins","year":"2023","unstructured":"Watkins C, Paulo T, B\u00fchrer C, Holekamp NM, Bagijn M. Comparative efficacy, durability and safety of faricimab in the treatment of diabetic macular edema: a systematic literature review and network meta-analysis. Adv Ther. 2023;40:5204\u201321.","journal-title":"Adv Ther"},{"key":"3223_CR26","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/s41433-022-02360-4","volume":"37","author":"RLW Hanson","year":"2023","unstructured":"Hanson RLW, Airody A, Sivaprasad S, Gale RP. Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review. Eye. 2023;37:2438\u201353.","journal-title":"Eye"},{"key":"3223_CR27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.oret.2022.03.024","volume":"6","author":"JQ Core","year":"2022","unstructured":"Core JQ, Pistilli M, Hua P, Daniel E, Grunwald JE, Toth CA, et al. Comparison of age-related macular degeneration treatments trials (CATT) research group. Predominantly persistent intraretinal fluid in the comparison of age-related macular degeneration treatments trials. Ophthalmol Retin. 2022;6:771\u201385.","journal-title":"Ophthalmol Retin"},{"key":"3223_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.oret.2021.12.007","volume":"6","author":"S Riedl","year":"2022","unstructured":"Riedl S, Vogl WD, Waldstein SM, Schmidt-Erfurth U, Bogunovi\u0107 H. Impact of intra- and subretinal fluid on vision based on volume quantification in the HARBOR trial. Ophthalmol Retin. 2022;6:291\u20137.","journal-title":"Ophthalmol Retin"},{"key":"3223_CR29","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41433-022-02264-3","volume":"37","author":"C Bailey","year":"2023","unstructured":"Bailey C, Cackett P, Kotagiri A, Mahmood S, Minos E, Narendran N, et al. Practical implementation of a q4-q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panel. Eye. 2023;37:1916\u201321.","journal-title":"Eye"},{"key":"3223_CR30","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41433-021-01487-0","volume":"35","author":"L Kodjikian","year":"2021","unstructured":"Kodjikian L, Parravano M, Clemens A, Dolz-Marco R, Holz FG, Munk MR, et al. Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations. Eye. 2021;35:2119\u201335.","journal-title":"Eye"},{"key":"3223_CR31","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1136\/bjophthalmol-2020-317161","volume":"105","author":"C Arpa","year":"2021","unstructured":"Arpa C, Khalid H, Chandra S, Wagner S, Fasler K, Faes L, et al. Ten-year survival trends of neovascular age-related macular degeneration at first presentation. Br J Ophthalmol. 2021;105:1688\u201395.","journal-title":"Br J Ophthalmol"},{"key":"3223_CR32","unstructured":"National Institute for Health and Care Excellence. Serious eye disorders: Quality Standard. Published 12 February 2019. www.nice.org.uk\/guidance\/qs180."},{"key":"3223_CR33","unstructured":"Kotagiri A, Gale R, Pearce I, Sivaprasad S, Cackett P, Elsherbiny S, et al. Intravitreal faricimab for neovascular age-related macular degeneration: Consensus pathway by an expert panel of UK retina specialists. Poster presented at The Royal College of Ophthalmologists annual congress; Birmingham, UK: 22\u201325 May 2023."},{"key":"3223_CR34","unstructured":"The Royal College of Ophthalmologists. Commissioning guidance\u2014age-related macular degeneration services. June 2021. https:\/\/www.rcophth.ac.uk\/resources-listing\/commissioning-guidance-age-related-macular-degeneration-services\/."},{"key":"3223_CR35","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.3390\/jcm12083013","volume":"12","author":"M Chorev","year":"2023","unstructured":"Chorev M, Haderlein J, Chandra S, Menon G, Burton BJL, Pearce I, et al. A multi-modal AI-driven cohort selection tool to predict suboptimal non-responders to aflibercept loading-phase for neovascular age-related macular degeneration: PRECISE study report 1. J Clin Med. 2023;12:3013.","journal-title":"J Clin Med"},{"key":"3223_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu PS, Allingham MJ, Cousins SW. Incomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82:100906.","journal-title":"Prog Retin Eye Res"},{"key":"3223_CR37","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00417-020-05000-3","volume":"259","author":"M Zola","year":"2021","unstructured":"Zola M, D\u2019Alessandro E, Sherif M, Nguyen A, De Azevedo D, Haeller C, et al. Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment. Graefes Arch Clin Exp Ophthalmol. 2021;259:1477\u201386.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3223_CR38","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.2147\/OPTH.S395279","volume":"16","author":"RB Rush","year":"2022","unstructured":"Rush RB, Rush SW. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2022;16:4041\u20136.","journal-title":"Clin Ophthalmol"},{"key":"3223_CR39","doi-asserted-by":"crossref","unstructured":"Khoramnia R, Nguyen QD, Kertes PJ, Ramsay LS, Vujosevic S, Anderesi M, et al. Exploring the role of retinal fluid as a biomarker for the management of diabetic macular oedema. Eye. 2024;38:54\u201360.","DOI":"10.1038\/s41433-023-02637-2"},{"key":"3223_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","volume":"238","author":"DM Brown","year":"2022","unstructured":"Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, et al. KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157\u201372.","journal-title":"Am J Ophthalmol"},{"key":"3223_CR41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/medicina59030629","volume":"59","author":"YC Chang","year":"2023","unstructured":"Chang YC, Huang YT, Hsu AY, Meng PP, Lin CJ, Lai CT, et al. Optical coherence tomography biomarkers in predicting treatment outcomes of diabetic macular edema after ranibizumab injections. Medicina. 2023;59:629.","journal-title":"Medicina"},{"key":"3223_CR42","unstructured":"Chakrabarti S, Gale R, Sivaprasad S, Bailey C, Yang Y, Peto T, et al. Intravitreal faricimab for diabetic macular oedema: Consensus pathway by an expert panel of UK retina specialists. Poster presented at The Royal College of Ophthalmologists annual congress; Birmingham, UK: 22\u201325 May 2023."},{"key":"3223_CR43","unstructured":"National Institute for Health and Care Excellence. Faricimab for treating diabetic macular oedema (TA799). Technology appraisal guidance. June 2022. www.nice.org.uk\/guidance\/ta799."},{"key":"3223_CR44","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.2147\/OPTH.S381503","volume":"16","author":"RB Rush","year":"2022","unstructured":"Rush RB, Rush SW. Faricimab for treatment-resistant diabetic macular edema. Clin Ophthalmol. 2022;16:2797\u2013801.","journal-title":"Clin Ophthalmol"},{"key":"3223_CR45","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1097\/IAE.0000000000002302","volume":"38","author":"SB Bressler","year":"2018","unstructured":"Bressler SB, Odia I, Glassman AR, Danis RP, Grover S, Hampton GR, et al. Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR.net Protocol I 5-year report. Retina. 2018;38:1896\u2013904.","journal-title":"Retina"},{"key":"3223_CR46","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"JA Wells","year":"2016","unstructured":"Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123:1351\u20139.","journal-title":"Ophthalmology"},{"key":"3223_CR47","unstructured":"National Institute for Health and Care Excellence. Guideline. Diabetic retinopathy: management and monitoring. Draft for consultation, August 2023. https:\/\/www.nice.org.uk\/guidance\/gid-ng10256\/documents\/draft-guideline."},{"key":"3223_CR48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.visres.2017.06.015","volume":"139","author":"EA Urias","year":"2017","unstructured":"Urias EA, Urias GA, Monickaraj F, McGuire P, Das A. Novel therapeutic targets in diabetic macular edema: beyond VEGF. Vis Res. 2017;139:221\u20137.","journal-title":"Vis Res"},{"key":"3223_CR49","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3390\/jcm13051327","volume":"13","author":"ML Salvetat","year":"2024","unstructured":"Salvetat ML, Pellegrini F, Spadea L, Salati C, Musa M, Gagliano C, et al. The treatment of diabetic retinal edema with intravitreal steroids: how and when. J Clin Med. 2024;13:1327.","journal-title":"J Clin Med"},{"key":"3223_CR50","unstructured":"National Institute for Health and Care Excellence. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824). Technology appraisal guidance. September 2022. https:\/\/www.nice.org.uk\/guidance\/ta824."},{"key":"3223_CR51","unstructured":"National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953). Technology appraisal guidance. March 2024. https:\/\/www.nice.org.uk\/guidance\/ta953."},{"key":"3223_CR52","unstructured":"Scottish Medicines Consortium. Fluocinolone acetonide 190 micrograms intravitreal implant (Iluvien\u00ae) SMC No. (864\/13). January 2014. https:\/\/www.scottishmedicines.org.uk\/media\/1737\/fluocinolone__iluvien__resubmission_final_january_2014_for_website.pdf."},{"key":"3223_CR53","unstructured":"NHS England. Operational note: Commissioning recommendations following the national procurement for medical retinal vascular medicines. National procurement for Anti-VEGF and Intravitreal Corticosteroids. August 2022. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2022\/08\/B1720-Commissioning-recommendations-following-national-procurement-medical-retinal-vascular-medicines-August-2.pdf."},{"key":"3223_CR54","unstructured":"The Royal College of Ophthalmologists. Intravitreal injection therapy. August 2018. https:\/\/www.rcophth.ac.uk\/resources-listing\/intravitreal-injection-therapy\/."},{"key":"3223_CR55","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"J Sahni","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126:1155\u201370.","journal-title":"Ophthalmology"},{"key":"3223_CR56","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","volume":"138","author":"J Sahni","year":"2020","unstructured":"Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:955\u201363.","journal-title":"JAMA Ophthalmol"},{"key":"3223_CR57","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:964\u201372.","journal-title":"JAMA Ophthalmol"},{"key":"3223_CR58","unstructured":"VABYSMO\u00ae (faricimab-svoa) injection, for intravitreal use. Highlights of prescribing information; Genentech, Inc., October 2023."},{"key":"3223_CR59","unstructured":"EYLEA\u00ae (aflibercept) injection, for intravitreal use. Highlights of prescribing information; Regeneron Pharmaceuticals, Inc., December 2023."},{"key":"3223_CR60","unstructured":"Eylea 40 mg\/ml solution for injection in pre-filled syringe [Summary of Product Characteristics]; Bayer plc, UK, November 2023."},{"key":"3223_CR61","unstructured":"Lucentis 10 mg\/ml solution for injection [Summary of Product Characteristics]; Novartis Pharmaceuticals UK Limited, July 2023."},{"key":"3223_CR62","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1097\/IAE.0000000000002195","volume":"38","author":"AM Khanani","year":"2018","unstructured":"Khanani AM, Eichenbaum D, Schlottmann PG, Tuomi L, Sarraf D. Optimal management of pigment epithelial detachments in eyes with neovascular age-related macular degeneration. Retina. 2018;38:2103\u201317.","journal-title":"Retina"},{"key":"3223_CR63","first-page":"142","volume":"112","author":"D Sarraf","year":"2014","unstructured":"Sarraf D, Joseph A, Rahimy E. Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2014;112:142\u201359.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"3223_CR64","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1038\/s41433-022-02149-5","volume":"36","author":"R Gale","year":"2022","unstructured":"Gale R, Cox O, Keenan C, Chakravarthy U. Health technology assessment of new retinal treatments; the need to capture healthcare capacity issues. Eye. 2022;36:2236\u20138.","journal-title":"Eye"},{"key":"3223_CR65","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.2147\/OPTH.S384995","volume":"16","author":"EA Meer","year":"2022","unstructured":"Meer EA, Oh DH, Brodie FL. Time and distance cost of longer acting anti-VEGF therapies for macular degeneration: contributions to drug cost comparisons. Clin Ophthalmol. 2022;16:4273\u20139.","journal-title":"Clin Ophthalmol"},{"key":"3223_CR66","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.2147\/DDDT.S427416","volume":"17","author":"GD Panos","year":"2023","unstructured":"Panos GD, Lakshmanan A, Dadoukis P, Ripa M, Motta L, Amoaku WM. Faricimab: transforming the future of macular diseases treatment - a comprehensive review of clinical studies. Drug Des Devel Ther. 2023;17:2861\u201373.","journal-title":"Drug Des Devel Ther"},{"key":"3223_CR67","unstructured":"Bakri SJ, Tabano D, Borkar D, Garmo V, Ahmed A, Myers R, et al. Real-world outcomes and treatment patterns with faricimab in AMD FARETINA. Paper presented at American Academy of Ophthalmology 2023 retina subspecialty day; San Francisco, CA, USA: 3\u20136 November 2023."},{"key":"3223_CR68","unstructured":"Borkar D, Tabano D, Garmo V, Leng T, Shaia J, Kuo BL, et al. Early treatment patterns and outcomes in patients with diabetic macular edema treated with faricimab: the FARETINA-DME Study. Paper presented at American Society of Retina Specialists annual meeting; Seattle, WA, USA: 28 July\u20131 August 2023."},{"key":"3223_CR69","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye. 2023;37:3574\u201381.","journal-title":"Eye"},{"key":"3223_CR70","doi-asserted-by":"crossref","unstructured":"Pandit SA, Momenaei B, Wakabayashi T, Mansour HA, Vemula S, Durrani AF, et al. Real-world outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol Retina. 2024;8:360\u20136.","DOI":"10.1016\/j.oret.2023.10.018"},{"key":"3223_CR71","unstructured":"Talks J, de Salvo G, Patel PJ, de Silva SR, Gale RP, McKibbin M, et al. FARWIDE-nAMD: Early treatment patterns of faricimab among neovascular age-related macular degeneration patients in the UK. Paper presented at 23rd European Society of Retina Specialists Congress; Amsterdam, The Netherlands: 5\u20138 October 2023."},{"key":"3223_CR72","unstructured":"Bailey C, Peto T, Downey L, Kiire C, Pearce I, Reynolds R, et al. FARWIDE-DMO: Early treatment patterns of faricimab among DMO patients in the UK. Paper presented at 23rd European Society of Retina Specialists Congress; Amsterdam, The Netherlands: 5\u20138 October 2023."},{"key":"3223_CR73","doi-asserted-by":"crossref","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A, Varma D, Habib M, Kotagiri A, et al. Outcomes of treatment-resistant neovascular age-related macular degeneration switched from aflibercept to faricimab. Ophthalmol Retina. 2024;8:537\u201344.","DOI":"10.1016\/j.oret.2023.11.015"},{"key":"3223_CR74","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/OPTH.S125676","volume":"11","author":"K Spooner","year":"2017","unstructured":"Spooner K, Hong T, Wijeyakumar W, Chang AA. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis. Clin Ophthalmol. 2017;11:161\u201377.","journal-title":"Clin Ophthalmol"},{"key":"3223_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-022-00373-5","volume":"8","author":"AE Sepetis","year":"2022","unstructured":"Sepetis AE, Clarke H, Gupta B. Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings. Int J Retin Vitreous. 2022;8:23.","journal-title":"Int J Retin Vitreous"},{"key":"3223_CR76","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.2147\/OPTH.S402142","volume":"17","author":"FWB Sanders","year":"2023","unstructured":"Sanders FWB, Dumont Jones R, Jones DR, Phillips SV, Williams GS. Treatment of diabetic macular edema or macular edema following retinal vein occlusion based on repeated injection of the dexamethasone intravitreal implant: a retrospective real-world analysis. Clin Ophthalmol. 2023;17:3177\u201387.","journal-title":"Clin Ophthalmol"},{"key":"3223_CR77","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00592-018-1151-x","volume":"55","author":"C Busch","year":"2018","unstructured":"Busch C, Zur D, Fraser-Bell S, La\u00edns I, Santos AR, Lupidi M, et al. International Retina Group. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018;55:789\u201396.","journal-title":"Acta Diabetol"},{"key":"3223_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9","volume":"10","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, Thomas M, Fong RD, Smith K, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retin Vitreous. 2024;10:5.","journal-title":"Int J Retin Vitreous"},{"key":"3223_CR79","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.15201","volume":"101","author":"RP Gale","year":"2023","unstructured":"Gale RP, Finger RP, Eldem B, Aslam T, Barratt J, Daien V, et al. The management of neovascular age-related macular degeneration: a systematic literature review of patient-reported outcomes, patient mental health and caregiver burden. Acta Ophthalmol. 2023;101:e26\u201342.","journal-title":"Acta Ophthalmol"},{"key":"3223_CR80","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2147\/DMSO.S214098","volume":"12","author":"KL Spooner","year":"2019","unstructured":"Spooner KL, Guinan G, Koller S, Hong T, Chang AA. Burden of treatment among patients undergoing intravitreal injections for diabetic macular oedema in Australia. Diabetes Metab Syndr Obes 2019;12:1913\u201321.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"3223_CR81","unstructured":"Narayan A, Watson S-L. Faricimab: the solution to treatment resistant neovascular age related macular degeneration? A real-world study. Poster presented at The Royal College of Ophthalmologists annual congress 2023; Birmingham, UK: 22\u201325 May 2023."},{"key":"3223_CR82","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M15-0288","volume":"163","author":"WP Battisti","year":"2015","unstructured":"Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163:461\u20134.","journal-title":"Ann Intern Med"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03223-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03223-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03223-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T11:03:57Z","timestamp":1730977437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03223-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":82,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3223"],"URL":"https:\/\/doi.org\/10.1038\/s41433-024-03223-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4085200\/v1","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LD: Advisory board attendances for and speaker honoraria from Alimera Sciences, AbbVie, Bayer, Biogen, Novartis and Roche; travel grants from AbbVie, Bayer and Novartis. SS: Financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, EyePoint Pharmaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi. Is the current Editor in Chief of Eye. RC: Advisory board attendances for and speaker honoraria and travel grants from Roche, Bayer, Novartis and Alimera Sciences. CB: Advisory board attendances for and honoraria and travel support from Alimera Sciences, Apellis, Bayer, Boehringer Ingelheim, Janssen Pharmaceuticals, Novartis and Roche. SC: Honoraria from and consultancy for Roche, AbbVie and Alimera Sciences and travel support from Bayer and Alimera Sciences. SE: Advisory board attendances for and travel support from AbbVie, Alimera Sciences, Bayer, Novartis, Roche and Topcon. JP: Consultancy for and travel support from Bayer and Roche. GS: Advisory board attendances for and honoraria and travel support from Bayer and Roche. S-LW: Advisory board attendances for and honoraria and travel support from Roche, Bayer, and Novartis. GW: Honoraria from Roche. AP: Employee of Roche Products Limited. SK: Employee of Roche Products Limited. AL: Travel support from Roche; equity in EyeBio.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}